Financial Data and Key Metrics Changes - The company reported first quarter adjusted diluted EPS of $2.90, consistent with previous expectations, with full-year 2025 adjusted EPS expectations remaining unchanged at greater than $7.25 [5][24][37] - Premium and service revenue for Q1 was $42.5 billion, with an increase in full-year revenue guidance to a midpoint of $165 billion, up from $159 billion [26][38] - The adjusted SG&A expense ratio decreased to 7.9% from 8.7% year-over-year, driven by revenue growth and expense discipline [35] Business Line Data and Key Metrics Changes - Medicaid membership was stable at approximately 12.9 to 13 million members, with a Medicaid HBR of approximately 93%, showing slight improvement from 93.4% in Q4 2024 [27][28] - The Medicare segment performed in line with expectations, with Medicare Advantage membership contributing an additional $1 billion to the 2025 revenue outlook due to better-than-expected retention [16][31] - The commercial segment saw strong growth, with a Q1 HBR of 75.0%, up from 73.3% the previous year, driven by new marketplace members [34] Market Data and Key Metrics Changes - The company noted an increase in bipartisan support for extending health care premium tax credits, with 78% of swing voters supporting the extension [9] - The expiration of enhanced premium tax credits is anticipated to be addressed by Congress, with significant implications for the marketplace [10][23] - The company is preparing for potential impacts from proposed marketplace integrity and affordability rules, which could influence market dynamics starting in 2026 [22][42] Company Strategy and Development Direction - The company is focused on margin recovery and aligning rates with member acuity, with expectations that Medicaid will return to pre-pandemic margin levels [11][13] - Strategic initiatives include expanding Medicaid managed care into rural areas and enhancing the Medicare Advantage value proposition [14][16] - The company is committed to navigating the evolving policy landscape while advocating for sound health care policy [7][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to manage through a dynamic policy landscape, noting that broad support for Medicaid benefit cuts is lacking [7][8] - The company anticipates continued momentum in discussions with state partners regarding rate negotiations and acuity data [75] - Management remains optimistic about long-term growth prospects, emphasizing the attractiveness of end markets and the potential for market share capture [24][25] Other Important Information - The company experienced $130 million in incremental medical expenses due to an active flu season, which offset underlying improvements in medical loss ratio [12][28] - The company is actively engaging with CMS on proposed rules that could impact the marketplace and is preparing for various potential outcomes [22][23] Q&A Session Summary Question: Details on flu-related costs - Management clarified that the $130 million in flu-related costs was tracked using a consistent definition and was isolated to Medicaid, with some flu impact seen in Medicare but not at the same level [49][51] Question: Long-term earnings outlook - Management confirmed that the long-term earnings potential remains optimistic, with opportunities for margin expansion in Medicaid and Medicare segments [54][56] Question: Impact of public exchange subsidies - Management indicated that the estimate of a $1 impact per share from the potential loss of enhanced APTCs remains valid, with ongoing discussions about the implications of work requirements [57][61] Question: Risk adjustment and membership growth - Management noted that risk adjustment numbers are consistent with expectations, and the majority of new membership remains subsidized, aligning with the company's focus on low-income populations [99][96] Question: Specialty drug trends - Management highlighted that specialty drug utilization trends are being closely monitored, particularly in Medicaid, with high-cost drugs impacting overall costs [118][120]

Core Insights - Centene reported $46.62 billion in revenue for Q1 2025, a 15.4% year-over-year increase, with an EPS of $2.90 compared to $2.26 a year ago, exceeding Zacks Consensus Estimates for both revenue and EPS [1] - The company delivered a revenue surprise of +7.24% and an EPS surprise of +22.88% compared to analyst expectations [1] Financial Performance Metrics - Total Medical Health Benefits loss ratio was 87.1%, better than the estimated 87.9% [4] - Membership in High Acuity Medicaid stood at 1.59 million, matching analyst estimates [4] - Medicaid membership reached 12.96 million, slightly above the 12.94 million estimate [4] - SG&A Expense Ratio was 7.9%, lower than the estimated 8.4% [4] - Premium and service revenues totaled $42.49 billion, exceeding the $40.12 billion estimate, reflecting a 16.9% year-over-year increase [4] - Premium revenues were $41.71 billion, surpassing the $39.35 billion estimate, marking a 17.4% year-over-year change [4] - Service revenues were $777 million, slightly above the $768.54 million estimate, but a 3.8% decrease year-over-year [4] - Premium tax revenues were $4.13 billion, exceeding the $3.52 billion estimate, with a 1.5% year-over-year increase [4] - Commercial premium and service revenues reached $10.15 billion, significantly above the $9.04 billion estimate, representing a 30.9% year-over-year increase [4] - Medicare premium and service revenues were $8.76 billion, exceeding the $8.54 billion estimate, with a 47.6% year-over-year increase [4] - Medicaid premium and service revenues totaled $22.30 billion, above the $21.45 billion estimate, reflecting a 3.9% year-over-year increase [4] - Other premium and service revenues were $1.28 billion, exceeding the $1.22 billion estimate, with a 7.6% year-over-year increase [4] Stock Performance - Centene's shares returned +2.2% over the past month, contrasting with the Zacks S&P 500 composite's -4.8% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]

Core Insights - Centene (CNC) reported quarterly earnings of $2.90 per share, exceeding the Zacks Consensus Estimate of $2.36 per share, and up from $2.26 per share a year ago, representing an earnings surprise of 22.88% [1] - The company achieved revenues of $46.62 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 7.24% and increasing from $40.41 billion year-over-year [2] Earnings Performance - Over the last four quarters, Centene has surpassed consensus EPS estimates three times, indicating strong earnings performance [2] - The company also topped consensus revenue estimates four times in the last four quarters, showcasing consistent revenue growth [2] Stock Performance - Centene shares have increased approximately 1.7% since the beginning of the year, contrasting with the S&P 500's decline of -6.8% [3] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $2.16 on revenues of $43.09 billion, while for the current fiscal year, the estimate is $7.13 on revenues of $172.83 billion [7] - The estimate revisions trend for Centene is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Medical - HMOs industry, to which Centene belongs, is currently ranked in the bottom 22% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Centene's stock performance [5]

-- Diluted EPS of $2.63; Adjusted Diluted EPS of $2.90 -- First quarter 2025 adjusted diluted EPS of $2.90, up 28% from $2.26 in the first quarter of 2024. 17% year-over-year premium and service revenue growth. Membership increases of 29% in Marketplace and 22% in Medicare PDP, compared to the first quarter of 2024. Increased 2025 premium and service revenues guidance by $6.0 billion driven by outperformance in Marketplace enrollment and Medicare member retention.ST. LOUIS, April 25, 2025 /PRNewswire/ -- Ce ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ ____________________________________________ Commission file number: 001-31826 ____________________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ____________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ...

Core Insights - A collaboration between Health Net, Dignity Health, and Vivant Health has significantly improved care coordination for Medi-Cal members in Sacramento County, reducing unnecessary hospital days and increasing follow-up appointments [1][2][3] Group 1: Partnership Impact - The initiative has avoided over 400 unnecessary inpatient days in hospitals, showcasing the effectiveness of the collaborative approach [6] - There has been a 20-percentage point increase in the percentage of patients who had a primary care provider or specialist follow-up appointment after discharge, rising from 76% to 96% [6] - The partnership emphasizes tailored care for patients, enhancing the overall patient experience and setting new healthcare standards [3][4] Group 2: Care Model and Social Determinants - The collaboration integrates new care models aligned with California's CalAIM program, addressing individual social needs such as housing and care navigation [3][4] - A multidisciplinary team, including physicians, nurses, case managers, and social workers, focuses on social determinants of health, significantly improving patient outcomes [4] Group 3: Organizational Background - Health Net, a Centene Corporation company, serves over three million members in California and offers a range of health plans and services [5] - Dignity Health operates a multi-state nonprofit network with over 10,000 physicians and 60,000 employees, dedicated to providing affordable patient-centered care [7] - Vivant Health has been a leader in healthcare innovation for over 30 years, serving over 300,000 patients in California and promoting health equity [8]

Core Insights - Aisera has appointed Gary Pelczar as Vice President of Channels and Alliances to enhance its strategic partnerships and expand its market reach [1][2][3] - Pelczar brings over a decade of experience in developing strategic alliances, having previously held key roles at Voltron Data and Devo, where he achieved significant revenue growth [2][3] - Aisera's Agentic AI platform is positioned to transform enterprise technology and drive sustained growth through synergistic partnerships [3][4] Company Overview - Aisera is a provider of agentic AI platforms aimed at improving work experiences, productivity, and reducing operational costs for businesses [4] - Founded in 2017, Aisera is supported by prominent investors such as Goldman Sachs and Cisco Ventures, and its solutions are utilized by major brands and Fortune 500 companies [5][6] - The company is headquartered in Palo Alto, California, with a global presence across multiple countries including the USA, Greece, India, Canada, UK, and France [6]